LeMaitre Vascular's Q4 2019: A Growth Spurt or Just a Blip?

Today, LeMaitre Vascular, Inc. (Nasdaq: LMAT), a company that provides vascular devices, implants, and services, released its Q4 2019 financial results. Investors were keen to see if the company would deliver an earnings surprise and how it would stack up against the EPS consensus. Spoiler alert: it was a mixed bag, but in a way that might just keep the excitement alive for 2020.

Record Sales, But What?s the Bottom Line?

LeMaitre reported record sales of $30.2 million, marking a 6% increase from Q4 2018. However, organic growth was flat, which might raise eyebrows among analysts. While revenue forecasts were optimistic, the operating income took a hit, falling to $4.9 million?a staggering 31% drop. Excluding special items, that decline was still a hefty 12%.

Net income also saw a downturn, landing at $4.6 million, down 23% year-over-year. The earnings per share (EPS) reported was $0.23, reflecting a 25% decrease, though excluding special items, it showed a modest 3% increase. The decline in profitability raises questions: is this a temporary dip, or a sign of deeper issues within the company?

Gross Margins Take a Hit

Gross margin decreased to 66.0% from 67.7% in the prior year. This decline was attributed to a less favorable sales mix and lower-margin revenues from recent acquisitions, compounded by the strong U.S. dollar. The company?s strategy of growth through acquisition might be backfiring slightly?was it too aggressive? Investors will want to keep a close eye on how these acquisitions perform going forward.

Guidance for 2020: Optimism Amidst Challenges

Chairman and CEO George LeMaitre expressed optimism about future growth, projecting a 10% increase in sales and 17% growth in operating income for 2020. That?s a bold claim, especially considering the current operational backdrop. The guidance for Q1 2020 sales is set between $30.5 million and $31.7 million, with an EPS forecast of $0.14 to $0.17. This suggests a potential decline in earnings, as the midpoint reflects a 10% drop compared to the previous year.

Sector Implications and Investor Sentiment

The performance of LeMaitre Vascular could signal broader trends within the vascular device market. With increasing competition and potential economic headwinds, investors must weigh the risks against the company?s growth potential. If LeMaitre can successfully navigate these choppy waters, it may set a precedent for peers in the industry.

In conclusion, while the numbers from Q4 2019 might raise concerns about profitability and operational efficiency, the company?s ambitious guidance for 2020 could invigorate investor interest. As we anticipate quarterly earnings from similar sector players, the results from LMAT provide a critical lens through which to evaluate the landscape of vascular device companies.